Navigation Links
His Royal Highness The Duke of York Helps Launch UK-Based Pharmaceutical Company, ProStrakan, in the United States
Date:2/14/2008

NEW YORK, Feb. 14 /PRNewswire/ -- His Royal Highness, The Duke of York, was the guest of honour today at a lunch held to mark the United States launch of UK-based specialty pharmaceutical company, ProStrakan Group plc (LSE: PSK). ProStrakan's first US product, Sancuso, is currently under consideration for licensing by the US Food & Drug Administration.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080214/NYTH111 )

Prince Andrew is visiting the United States as the UK's Special Representative for International Trade & Investment. He accepted the invitation to today's lunch after visiting ProStrakan's headquarters in Galashiels, Scotland, last year at which time he was briefed on ProStrakan's plans for expansion into the US.

Commenting on today's visit, The Duke of York said:

"It gives me great pleasure to see ProStrakan establish itself in the United States. I was hugely impressed by the company's ambition and drive when I visited their headquarters in Galashiels last year. I am committed to doing everything I can to help UK companies like ProStrakan expand still further into the global marketplace."

ProStrakan's Chief Executive Officer, Dr Wilson Totten, the host of the lunch, said:

"ProStrakan was founded on a commitment to developing innovative products to meet the needs of patients. With that, we are pleased to announce our US business and today's event has marked our arrival here in the best possible way.

"We were delighted when Prince Andrew visited us in Galashiels last year but to have him join us as guest of honour today here in New York was a special privilege."

Also attending today's lunch were guests representing ProStrakan's US business partners, including Ron Wooten, Executive Vice President of Quintiles Transnational and President of NovaQuest; Patrick Jordan, Vice President of NovaQuest; and advisors and staff in the US. The lunch was held at Manhattan's Carlyle Hotel.

ProStrakan has established its US headquarters in Bedminster, New Jersey. The company has partnered with NovaQuest to recruit a 75-person sales force to commercialize ProStrakan's products in the US. NovaQuest is the strategic partnering group of Quintiles Transnational, the world's leading pharmaceutical services company. Once recruited, it is planned that the sales force will promote ProStrakan's Sancuso.

Sancuso is a transdermal patch that delivers granisetron, an established 5-HT3 receptor antagonist, steadily into the bloodstream over a number of days, helping to prevent the side-effects of nausea and vomiting in patients undergoing chemotherapy without the need for injection or having to swallow pills.

ProStrakan

ProStrakan Group plc is a rapidly growing international specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. EU-wide sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, France, Germany, Spain and other EU countries. http://www.prostrakan.com

NovaQuest

NovaQuest, the strategic partnering group of Quintiles Transnational, is an industry pioneer in offering tailored financial and operational solutions that help pharmaceutical and biotech companies overcome development and commercialization challenges. Its unique managed partnership approach ensures sponsorship by senior-level executives; access to global development and commercial resources and expertise; and efficient operational delivery of services. Since 2000, NovaQuest partnerships have committed more than $2 billion in capital to pharmaceutical and biotech companies of all sizes. For more information, please visit http://www.novaquest.com.


'/>"/>
SOURCE ProStrakan Group plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share
2. Royalty Pharma Acquires a Portion of Northwestern Universitys Royalty Interest in Lyrica(R) for $700 Million
3. Unilens Vision Reports Record First Quarter Earnings and Royalty Income
4. British Royal highlights anesthesia crisis in the developing world
5. Virtual Hold Technology Donates Toys, Helps Raise Money for WKDDs Annual Radiothon for Akron Childrens Hospital
6. Oracle Helps Mayo Clinic Improve Information Management
7. Sucking Out Clot Debris Helps Heart Attack Patients
8. Wild Animal Crunch(TM) Helps Moms Tame Families Hunger
9. Drug Helps Prevent Breast-Feeding Moms From Passing on HIV
10. VMware Desktop Virtualization Helps Healthcare Providers Improve Patient Care
11. Kelloggs Frosted Flakes Gold(TM) Helps Moms Get the Gold
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... ... is Men’s Health Month and the focus is on prostate cancer. Second only ... and the third most common cause of cancer related death today; lung cancer remains in ... diagnosed with prostate cancer during his lifetime. Those at highest risk are men ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
(Date:6/24/2017)... ... June 24, 2017 , ... The weather is heating up ... Home and business owners should be aware that the summer months provide more than ... mechanical locks and keys can be negatively affected from direct exposure to the sun. ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode ... of Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers ... RIQI’s Care Management Alerts and Dashboards provide near real-time data about patients admitted ...
(Date:6/23/2017)... Long Beach, CA (PRWEB) , ... June 23, 2017 , ... ... (ANRF) has earned its ninth consecutive four-star rating from premier online charity evaluator, Charity ... ANRF in the top 1% of all charities reviewed by Charity Navigator and earns ...
Breaking Medicine News(10 mins):
(Date:5/24/2017)...  ivWatch LLC today announced the launch of ... enable seamless integration of ivWatch,s groundbreaking IV infiltration ... and other devices. By integrating ivWatch technology into ... health care customers deliver a higher level of ... therapy. "The ivWatch OEM Board provides ...
(Date:5/22/2017)... May 22, 2017  As the specialty pharmacy ... continue to make the revolutionary shift from volume-based ... for ensuring positive patient outcomes and shaping the ... shifting focus away from clinical trials and toward ... long-term specialty drug therapy utilization in precise patient ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, chief ... leader in noninvasive pain relief, was awarded a 2017 ... magazine. Baxter was recognized at the MM&M Top 40 ... York City on May 10, 2017. The ... biopharma industry go "beyond the pill."  "Innovation ...
Breaking Medicine Technology: